Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking

Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition

(2023) Alvan Amos et al.   BMC CANCER

Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study

(2023) Jan Lycke et al.   CNS DRUGS

Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase

(2023) Shuying Cao et al.   Chemical Biology & Drug Design

A patent review of human dihydroorotate dehydrogenase (hDHODH) inhibitors as anticancer agents and their other therapeutic applications (1999-2022)

(2023) Vivek K. Vyas et al.   Recent Patents on Anti-Cancer Drug Discovery

Uridine Inhibits Hepatocellular Carcinoma Cell Development by Inducing Ferroptosis

(2023) Liuliu Zi et al.   Journal of Clinical Medicine

Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis

(2023) Qi Wu et al.   Multiple Sclerosis and Related Disorders

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives

(2022) Lele Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study

(2022) Salvatore Galati et al.   MOLECULES

A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects

(2022) Ajit Nair et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells

(2022) Kyung U. Hong et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Targeting lipid metabolism for ferroptotic cancer therapy

(2022) Minhua Luo et al.   APOPTOSIS

Synthesis and biological evaluation of new quinoline‐4‐carboxylic acid‐chalcone hybrids as dihydroorotate dehydrogenase inhibitors

(2022) Milena M. Petrović et al.   ARCHIV DER PHARMAZIE

Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma

(2022) William D. Gwynne et al.   CANCER CELL

Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold

(2022) Chungen Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach

(2022) Asmaa Khairy et al.   Scientific Reports

DHODH and cancer: promising prospects to be explored

(2021) Yue Zhou et al.   Cancer & Metabolism

Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment

(2021) Chungen Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Teriflunomide: Pediatric First Approval

(2021) Julia Paik   PEDIATRIC DRUGS

Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability

(2020) Gergana Popova et al.   JOURNAL OF MEDICINAL CHEMISTRY

Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor

(2019) Godefridus J. Peters   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

(2018) Marco L. Lolli et al.   Recent Patents on Anti-Cancer Drug Discovery

Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer

(2018) Joseph T. Madak et al.   PHARMACOLOGY & THERAPEUTICS